Diffuse alveolar hemorrhage: Difference between revisions
Perobinson (talk | contribs) |
Perobinson (talk | contribs) |
||
| Line 42: | Line 42: | ||
===Management=== | ===Management=== | ||
General principles | |||
* Focus on airway stabilization | |||
* IV corticosteroids - high dose Methylprednisilone Q6H | |||
===Disposition=== | ===Disposition=== | ||
Revision as of 16:23, 13 June 2016
Background
- Diffuse Alveolar Hemorrhage (DAH) is a life-threatening condition.
- It is a subset of Pulmonary hemorrhage involving the microcirculation involving alveolar microvasculature.
- Most commonly the result of systemic vasculitis. [1]
Clinical Features
- Hemoptysis
- Anemia
- Diffuse lung infiltrates
- Acute respiratory failure
Differential Diagnosis
Idiopathic small vessel vasculitis
- Wegener's granulomatosis
- Churg-Straus syndrome
- Microscopic polyangitis
Primary immune complex-mediated vasculitis
- Goodpasture's syndrome
- Henoch-Schonlein purpura
Secondary vasculitis
- Systemic lupus erythematosus
- Rheumatoid arthritis
- Mixed connective tissue disease
- Polymyositis/Dermatomyositis
Acute lung transplant rejection
Drug induced (ie. chemotherapy, amiodarone, propylthiouracil)
ARDS
Coagulopathy
Pulmonic veno-occlusive disease
Mitral stenosis
Diagnosis
Management
General principles
- Focus on airway stabilization
- IV corticosteroids - high dose Methylprednisilone Q6H
Disposition
- ↑ Park M. Diffuse Alveolar Hemorrhage. Tuberc Resp Dis (Seoul) 2013. 74(4):151-162